India, Sept. 30 -- Eli Lilly and Company (LLY) announced detailed results from the Phase 3 ACHIEVE-4 trial showing that Foundayo (orforglipron) demonstrated cardiovascular safety while delivering sustained improvements in blood sugar control, body weight, and other cardiometabolic measures in adults with type 2 diabetes and obesity or overweight.
People with type 2 diabetes often face an increased risk of cardiovascular complications, making both blood sugar management and heart health important treatment goals.
The ACHIEVE-4 study evaluated whether Foundayo could provide metabolic benefits while maintaining cardiovascular safety.
ACHIEVE-4 was the largest and longest study of Foundayo conducted in type 2 diabetes to date and compared th...